Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Faina NakhlisSamuel M NimanNaoto T UenoElizabeth TrollSean RyanEren YehLaura WarrenJennifer BellonBeth HarrisonToshiaki IwaseH T Carisa Le-PetrossSadia SaleemMediget TeshomeGary J WhitmanWendy A WoodwardBeth OvermoyerSara M TolaneyMeredith ReganFilipa LynceRachel M LaymanPublished in: Breast cancer research and treatment (2023)
Among stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- transcription factor
- rectal cancer
- lymph node
- oxidative stress
- prognostic factors
- locally advanced
- squamous cell carcinoma
- stem cells
- mesenchymal stem cells
- young adults
- patient reported outcomes
- radiation therapy
- real time pcr
- patient reported
- replacement therapy